Long-term treatment with the drug upadacitinib significantly improved symptoms and quality of life compared to placebo in adolescents with moderate to severe atopic dermatitis after 76 weeks with strong evidence of safety, according to a recent Northwestern Medicine analysis of three international, randomized clinical trials.